A New Sildenafil Oral Film in Patients With Erectile Dysfunction
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase III, prospective, interventional, multi-center, randomized, double-blind,
fixed-dose, placebo-controlled, parallel group clinical study required by FDA to demonstrate
the efficacy and safety of Sildenafil oral film 50 mg, 75 mg and 100 mg as compared to
placebo in approximately 600 men clinically diagnosed with erectile dysfunction (ED).